Skip to main content

Advertisement

SpringerLink
Log in

Monitoring cancer therapy with PET: probably effective, but more research is needed

  • Focus on
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. http://nobelprize.org/nobel_prizes/medicine/laureates/1966/rous-bio.html.

  2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228–47.

    Article  PubMed  CAS  Google Scholar 

  3. Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med. 2009;39(3):210–32.

    Article  PubMed  Google Scholar 

  4. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15(8):2856–63.

    Article  PubMed  CAS  Google Scholar 

  5. Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2009;73(4):1228–34.

    PubMed  Google Scholar 

  6. Hamada K, Tomita Y, Inoue A, Fujimoto T, Hashimoto N, Myoui A, et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med. 2009;23(1):89–95.

    Article  PubMed  CAS  Google Scholar 

  7. Byström P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol. 2009;20(6):1057–61.

    Article  PubMed  Google Scholar 

  8. Cerfolio RJ, Bryant AS, Talati AA, Eloubeidi MA, Cerfolio RM, Winokur TS. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J Thorac Cardiovasc Surg. 2009 Mar;137(3):605–9. Erratum in: J Thorac Cardiovasc Surg. 2009 Jun;137(6):1581. Eloubeidi, Mohamad A [added].

  9. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19(6):1347–57.

    Article  PubMed  Google Scholar 

  10. Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer. 2009;45(2):290–9.

    Article  PubMed  CAS  Google Scholar 

  11. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009;15(6):1891–7.

    Article  PubMed  CAS  Google Scholar 

  12. Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging. 2009;53(2):158–66.

    PubMed  CAS  Google Scholar 

  13. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11(8):2785–808.

    Article  PubMed  CAS  Google Scholar 

  14. Eckelman WC, Reba RC, Kelloff GJ. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today. 2008;13(17–18):748–59.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author is grateful to Ms Catherine Wrenn for her advice and editorial support.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and Technologies and Center of Molecular and Cellular Imaging (IMAGO), University of Milan, Milan, Italy

    Giovanni Lucignani

  2. Department of Diagnostic Services, Unit of Nuclear Medicine, San Paolo Hospital, Via Antonio di Rudinì, 8, 20142, Milan, Italy

    Giovanni Lucignani

Authors
  1. Giovanni Lucignani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Lucignani.

Additional information

“Focus on…” abridgements aim to highlight papers published within the past year and draw extensively on the texts and summaries of the articles referenced. Less recent citations are also included when deemed useful to provide background information on the topic reviewed.

“About one person in six is now slain by neoplastic cells. Can nothing be done to combat these?” http://nobelprize.org/nobel_prizes/medicine/laureates/1966/rous-bio.html

Peyton Rous (1879–1970)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lucignani, G. Monitoring cancer therapy with PET: probably effective, but more research is needed. Eur J Nucl Med Mol Imaging 36, 1520–1525 (2009). https://doi.org/10.1007/s00259-009-1214-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1214-x

Keywords

Search

Navigation